NZ203299A - Process for the preparation of unilamellar liposomes in aqueous phase and their use as drug delivery systems by encapsulation - Google Patents

Process for the preparation of unilamellar liposomes in aqueous phase and their use as drug delivery systems by encapsulation

Info

Publication number
NZ203299A
NZ203299A NZ203299A NZ20329983A NZ203299A NZ 203299 A NZ203299 A NZ 203299A NZ 203299 A NZ203299 A NZ 203299A NZ 20329983 A NZ20329983 A NZ 20329983A NZ 203299 A NZ203299 A NZ 203299A
Authority
NZ
New Zealand
Prior art keywords
acid
hydrogen
process according
lecithin
aqueous phase
Prior art date
Application number
NZ203299A
Other languages
English (en)
Inventor
H Hauser
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NZ203299A publication Critical patent/NZ203299A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
NZ203299A 1982-02-17 1983-02-16 Process for the preparation of unilamellar liposomes in aqueous phase and their use as drug delivery systems by encapsulation NZ203299A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH98182 1982-02-17
CH23783 1983-01-17

Publications (1)

Publication Number Publication Date
NZ203299A true NZ203299A (en) 1987-02-20

Family

ID=25683978

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ203299A NZ203299A (en) 1982-02-17 1983-02-16 Process for the preparation of unilamellar liposomes in aqueous phase and their use as drug delivery systems by encapsulation

Country Status (14)

Country Link
US (1) US4619794A (enExample)
EP (1) EP0088046B1 (enExample)
AU (1) AU558810B2 (enExample)
CA (1) CA1219215A (enExample)
DE (1) DE3374837D1 (enExample)
DK (1) DK157063C (enExample)
ES (1) ES8407061A1 (enExample)
FI (1) FI79245C (enExample)
GR (1) GR81377B (enExample)
IE (1) IE54642B1 (enExample)
IL (1) IL67916A0 (enExample)
NO (1) NO168154C (enExample)
NZ (1) NZ203299A (enExample)
PT (1) PT76245B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306406B1 (en) 1990-07-19 2001-10-23 University Of Kentucky Research Foundation Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer

Families Citing this family (596)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
EP0152379A3 (de) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
CH668554A5 (de) * 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US5283122A (en) * 1984-04-19 1994-02-01 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
EP0208764A4 (en) * 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
US4740375A (en) * 1985-02-25 1988-04-26 Technology Unlimited, Inc. Gelcores
US4736051A (en) * 1985-03-20 1988-04-05 Kao Corporation Process for the preparation of an alkali metal salt of a diester phosphoric acid
US5622713A (en) * 1985-09-17 1997-04-22 The Regents Of The University Of California Method of detoxifying animal suffering from overdose
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
MY101125A (en) * 1985-12-23 1991-07-31 Kao Corp Gel-like emulsion and o/w emulsions obtained from gel-like emulsion
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
US4888288A (en) * 1986-01-30 1989-12-19 Becton Dickinson And Company Vesicles resistant to enzyme lysis and use thereof in an enzyme assay
DE3776763D1 (enExample) * 1986-06-16 1992-03-26 The Liposome Co.,Inc., Princeton, N.J., Us
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
JPS63182029A (ja) * 1987-01-22 1988-07-27 Agency Of Ind Science & Technol リポソ−ム
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
FR2616328B1 (fr) * 1987-06-12 1990-03-02 Moet Hennessy Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de murier, ou au moins une flavone, en particulier une kuwanone et composition pharmaceutique, notamment dermatologique, a activite depigmentante, ou anti-inflammatoire, ou cosmetique, l'incorporant
AU618972B2 (en) * 1987-10-06 1992-01-16 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
US4946683A (en) * 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
EP0393145A4 (en) * 1987-12-22 1991-09-11 The Liposome Company, Inc. Spontaneous vesiculation of multilamellar liposomes
US5269979A (en) * 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US5133965A (en) * 1988-06-08 1992-07-28 Fountain Pharmaceuticals, Inc. Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
FR2638639A1 (fr) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5139803A (en) * 1989-02-09 1992-08-18 Nabisco, Inc. Method and liposome composition for the stabilization of oxidizable substances
US4994440A (en) * 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IL94103A0 (en) * 1989-04-25 1991-01-31 Nattermann A & Cie Water-containing formulations with phospholipids,their preparation and application
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
US5290563A (en) * 1989-07-27 1994-03-01 Laboratoire Des Stallergenes Method for combining a mixture of heterogeneous substances with liposomes
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
DE4005711C1 (enExample) * 1990-02-23 1991-06-13 A. Nattermann & Cie Gmbh, 5000 Koeln, De
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
US5165994A (en) * 1990-06-05 1992-11-24 University Of Delaware Spontaneous equilbrium surfactant vesicles
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
EP0467838A3 (en) * 1990-07-17 1992-09-02 Ciba-Geigy Ag Process for preparing an injectable liposome dispersion
FR2674128A1 (fr) * 1991-03-19 1992-09-25 Patrinove "vecteurs de structure capsulaire" et leurs applications dans le transport de substances ou principes actifs.
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5720973A (en) * 1993-02-18 1998-02-24 Knoll Aktiengesellschaft Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
IT1270678B (it) * 1994-10-20 1997-05-07 Bayer Ag Liposomi al chetoprofen
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US20040208922A1 (en) * 1995-06-07 2004-10-21 The Regents Of The University Of California Method for loading lipid like vesicles with drugs or other chemicals
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6723531B2 (en) * 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5766877A (en) 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
EP1577391A1 (en) 1996-10-25 2005-09-21 Human Genome Sciences, Inc. Neutrokine alpha
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US5827532A (en) * 1997-01-31 1998-10-27 The Reagents Of The University Of California Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
US6103706A (en) * 1997-04-29 2000-08-15 New York Blood Center, Inc. Methods for treating viral infections
CA2291221A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. 32 human secreted proteins
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6726924B2 (en) * 1997-09-04 2004-04-27 Biozone Laboratories, Inc. Oral liposomal delivery system
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
US6395514B1 (en) * 1997-11-21 2002-05-28 Human Genome Sciences, Inc. Polynucleotides encoding chemokineα-5
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
ES2329467T3 (es) 1998-02-04 2009-11-26 Genentech, Inc. Utilizacion de heterogublina como factor de crecimiento de celulas epiteliales.
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
DK2016951T3 (da) 1998-03-17 2012-09-24 Genentech Inc VEGF- og BMP1-homologe polypeptider
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6333318B1 (en) * 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
RU2207844C2 (ru) * 1998-12-23 2003-07-10 Идеа Аг. УСОВЕРШЕНСТВОВАННЫЙ ПРЕПАРАТ ДЛЯ МЕСТНОГО НЕИНВАЗИВНОГО ПРИМЕНЕНИЯ in vivo
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
WO2000046240A2 (en) 1999-02-03 2000-08-10 Amgen Inc. Polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
US6372722B1 (en) 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
MXPA02012747A (es) 2000-06-28 2003-09-25 Amgen Inc Moleculas del receptor de linfopoietina estromica timica y sus usos.
AU1796902A (en) 2000-11-28 2002-06-11 Amgen Inc Novel polypeptides involved in immune response
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
EP2270052B8 (en) 2001-06-26 2018-05-02 Amgen Inc. Antibodies to OPGL
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
JP4399260B2 (ja) 2001-08-24 2010-01-13 ニューレン ファーマシューティカルズ リミテッド 神経再生ペプチドおよび脳損傷治療におけるその使用方法
NZ530985A (en) 2001-08-29 2006-03-31 Genentech Inc Bv8 nucleic acids and polypeptides with mitogenic activity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
WO2003029407A2 (en) * 2001-09-26 2003-04-10 Merck & Co., Inc. Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
EP1930420A1 (en) 2001-09-26 2008-06-11 Merck & Co., Inc. Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
DE10148067A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft Hitzesterilisierbare Alkylphosphocholin-Liposome
DE10148066A1 (de) * 2001-09-28 2003-04-24 Max Planck Gesellschaft Liposome enthaltend (Ether)-Lysolecithine
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040106773A1 (en) * 2001-10-12 2004-06-03 Hao Wang Human tuberoinfundibular peptide of 39 residues
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
TWI347951B (en) 2002-09-06 2011-09-01 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
KR100489701B1 (ko) * 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CN104001158A (zh) 2003-03-12 2014-08-27 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US7291590B2 (en) 2003-06-12 2007-11-06 Queen's University At Kingston Compositions and methods for treating atherosclerosis
WO2005010151A2 (en) 2003-06-27 2005-02-03 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP1648998B1 (en) 2003-07-18 2014-10-01 Amgen Inc. Specific binding agents to hepatocyte growth factor
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
EP1684791A4 (en) 2003-10-27 2009-07-01 Amgen Inc COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
JP2007530015A (ja) * 2004-01-05 2007-11-01 バイオテック・スタジオ・リミテッド・ライアビリティ・カンパニー 生物治療学的、診断および研究試薬
JP4889505B2 (ja) 2004-02-02 2012-03-07 アンブレツクス・インコーポレイテツド 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
JP4705026B2 (ja) 2004-03-19 2011-06-22 ジェノミディア株式会社 血管内皮増殖促進遺伝子
EP1729804A2 (en) 2004-03-19 2006-12-13 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
US20050267029A1 (en) * 2004-04-02 2005-12-01 Ancsin John B Compounds which modulate amyloidogenesis and methods for their identification and use
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
JP4852539B2 (ja) 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
KR20070039593A (ko) 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
EP1786837B1 (en) 2004-08-04 2013-05-01 Amgen Inc., Antibodies to dkk-1
US8299083B2 (en) 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006037182A1 (en) 2004-10-06 2006-04-13 Agri-Biotech Pty Ltd Antibody production method
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
AU2005319404B2 (en) 2004-12-20 2011-10-20 Amgen Fremont Inc. Binding proteins specific for human Matriptase
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
CA2590429C (en) * 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
SG161209A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
MX2007007580A (es) 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
NZ555206A (en) 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20060154285A1 (en) * 2004-12-29 2006-07-13 Robishaw Janet D Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CA2605508A1 (en) 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
WO2006133089A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
KR101366450B1 (ko) 2005-06-21 2014-03-14 조마 테크놀로지 리미티드 ＩＬ-１β 결합성 항체 및 그의 단편
HRP20160875T1 (hr) 2005-07-18 2016-09-23 Amgen Inc. Humana anti-b7rp1 neutralizirajuća antitijela
CN101600475A (zh) 2005-07-27 2009-12-09 佛罗里达大学研究基金会有限公司 修正蛋白质错误折叠的小型化合物及其使用
DK1937824T3 (da) * 2005-08-18 2013-04-02 Ambrx Inc Sammensætninger af tRNA og anvendelser deraf
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
ATE500215T1 (de) * 2005-11-08 2011-03-15 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
JP2009515897A (ja) 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
KR20080079643A (ko) * 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 비-천연 아미노산을 포함하는 방법 및 조성물
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US8158588B2 (en) 2005-12-05 2012-04-17 Simon Delagrave Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
ATE552853T1 (de) 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
US20080317670A1 (en) * 2005-12-14 2008-12-25 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP2009535642A (ja) 2006-05-03 2009-10-01 ゲイシンガー クリニック 非アルコール性脂肪性肝炎（ｎａｓｈ）を診断及び予測する方法
US8114399B2 (en) 2006-05-17 2012-02-14 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US8124743B2 (en) 2006-06-01 2012-02-28 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US7666423B2 (en) 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
WO2008030613A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
JP5451390B2 (ja) * 2006-09-08 2014-03-26 アンブルックス，インコーポレイテッド 脊椎動物細胞内におけるサプレッサーｔｒｎａの転写
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
ES2618830T3 (es) 2006-12-08 2017-06-22 Lexicon Pharmaceuticals, Inc. Anticuerpos monoclonales contra ANGPTL3
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
US9249423B2 (en) * 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
KR20100019467A (ko) * 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
JP5443979B2 (ja) 2007-05-11 2014-03-19 備前化成株式会社 新規のロイコトリエン受容体アンタゴニスト
EP2164870B1 (en) 2007-06-27 2015-12-09 National University of Singapore Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
PT2188313T (pt) 2007-08-21 2017-12-12 Amgen Inc Proteínas de ligação ao antigénio c-fms humano
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
RU2504551C2 (ru) 2007-09-26 2014-01-20 УЗ ФАРМА ГмбХ Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
MX2010005317A (es) * 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
DK2391650T3 (en) 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
ES2572631T3 (es) * 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CA2726999C (en) 2008-06-09 2017-05-02 Ludwig-Maximilians-Universitaet Muenchen New drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
EP3629022A1 (en) 2008-07-25 2020-04-01 Richard W. Wagner Protein screening methods
WO2010030813A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
RU2581962C2 (ru) 2008-09-19 2016-04-20 Медиммун Ллк Нацеленные средства связывания, направленные на dll4, и их применение
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
EP2331070A1 (en) * 2008-09-26 2011-06-15 Phares Pharmaceutical Research N.V. Method of solubilising biologically active compounds
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
MX2011005505A (es) 2008-11-26 2011-09-01 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos.
US20120087870A1 (en) 2008-12-19 2012-04-12 Hentges Francois Novel caviidae allergens and uses thereof
WO2010072684A1 (en) 2008-12-22 2010-07-01 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
KR101040396B1 (ko) 2009-01-20 2011-06-09 한올바이오파마주식회사 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010092109A2 (en) 2009-02-13 2010-08-19 Novartis Ag Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
MY156542A (en) 2009-05-05 2016-02-26 Amgen Inc Fgf21 mutants and uses thereof
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
JP2012530493A (ja) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20120282266A1 (en) 2009-10-16 2012-11-08 Auckland Uniservices Limited Anti-neoplastic uses of artemin antagonists
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
SMT201700248T1 (it) 2009-11-02 2017-07-18 Univ Washington Composizioni terapeutiche di nucleasi e metodi
WO2011060371A2 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2525792A1 (en) 2010-01-19 2012-11-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
US9090707B2 (en) 2010-01-27 2015-07-28 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
WO2011099007A1 (en) 2010-02-10 2011-08-18 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
ES2629165T3 (es) 2010-02-12 2017-08-07 Chimerix, Inc. Métodos de tratamiento de una infección vírica
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
WO2011131626A1 (en) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP2566964B1 (en) 2010-05-07 2016-10-19 Centre National De La Recherche Scientifique Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
EP2571987B1 (en) 2010-05-21 2017-03-01 Peptimed, Inc. Reagents for treating cancer
JP6081911B2 (ja) 2010-06-14 2017-02-15 リケラ バイオメッド エスエーＬｙｋｅｒａ Ｂｉｏｍｅｄ Ｓａ Ｓ１００ａ４抗体およびその治療上の使用
CN103038253A (zh) 2010-06-18 2013-04-10 西伯尔科学有限公司 作为用来稳定生物屏障的活性剂的肽
SMT202400182T1 (it) 2010-08-17 2024-07-09 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2632951B1 (en) 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
JP6189215B2 (ja) 2010-11-01 2017-08-30 ペプチメッド， インコーポレイテッド 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CN103298490B (zh) 2010-11-24 2017-04-26 莱克康制药公司 结合背板胶质乙酰酯酶的抗体
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
ES2847304T3 (es) 2011-01-17 2021-08-02 Lykera Biomed S A Anticuerpos contra la proteína S100P para el tratamiento y diagnóstico de cáncer
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
PT2667715T (pt) 2011-01-27 2017-10-19 Neuren Pharmaceuticals Ltd Tratamento de perturbações do espetro do autismo utilizando o ácido glicil-l-2-metilpropil-l-glutâmico
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
MX2013010185A (es) 2011-03-10 2014-02-17 Genentech Inc Tratamiento de alteraciones con funcion de barrera vascular alterada.
EP2694552B1 (en) 2011-04-07 2017-10-11 Amgen Inc. Novel egfr binding proteins
WO2012138919A2 (en) 2011-04-08 2012-10-11 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR102161657B1 (ko) 2011-04-29 2020-10-06 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012154263A1 (en) 2011-05-10 2012-11-15 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2720539B1 (en) 2011-06-14 2018-10-24 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP2014520123A (ja) 2011-06-17 2014-08-21 アムジエン・インコーポレーテツド Ｃｌｅｃ−２を使用して代謝性障害を治療または改善させる方法
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
US9605083B2 (en) 2011-08-16 2017-03-28 Emory University JAML specific binding agents, antibodies, and uses related thereto
US9328386B2 (en) 2011-08-16 2016-05-03 Evotec (München) Gmbh Markers for susceptibility to an inhibitor of an Src-family kinase
JP2014526441A (ja) 2011-08-31 2014-10-06 アムジエン・インコーポレーテツド １型糖尿病の治療における使用のためのｆｇｆ２１
PE20141151A1 (es) 2011-09-22 2014-09-25 Amgen Inc Proteinas de union al antigeno cd27l
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US8906860B2 (en) 2011-10-14 2014-12-09 The Board Of Trustees Of The University Of Illinois Methods and compositions inhibiting tumor cell proliferation
US20130172265A1 (en) 2011-10-14 2013-07-04 The Board Of Trustees Of The University Of Illinois Methods and Compositions for Inhibiting Tumor Cell Proliferation
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1202252A1 (en) 2011-11-16 2015-09-25 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2601941A1 (en) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
JP6635655B2 (ja) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
EP2866821B1 (en) 2012-07-02 2018-11-14 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
CA2881818A1 (en) 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
BR112015012644A2 (pt) 2012-11-30 2017-12-19 Hoffmann La Roche método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
CA2906540C (en) 2013-03-15 2021-01-12 Amgen Inc. Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
TW201525001A (zh) 2013-03-15 2015-07-01 Amgen Res Munich Gmbh 包含ｎ－端ａｂｐ之單鏈結合分子
EP2970470B1 (en) 2013-03-15 2019-12-04 Amgen Inc. Human pac1 antibodies
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
SMT201700402T1 (it) 2013-04-09 2017-11-15 Lykera Biomed S A Anticorpi anti-s-100a7 per il trattamento e la diagnosi del cancro
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
US10501803B2 (en) 2013-05-21 2019-12-10 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
PT3004167T (pt) 2013-05-30 2018-11-13 Kiniksa Pharmaceuticals Ltd Proteínas de ligação ao antigénio do recetor da oncostatina m
EP2810648A1 (en) 2013-06-04 2014-12-10 Daniel Rauh Targeting domain-domain interaction for the identification of kinase modulators
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
EP3027642B1 (en) 2013-07-31 2020-08-19 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
SG11201601193TA (en) 2013-09-16 2016-04-28 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Mutant calreticulin for the diagnosis of myeloid malignancies
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
DK3063275T3 (da) 2013-10-31 2019-11-25 Resolve Therapeutics Llc Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
EP3104873B1 (en) 2014-02-13 2019-09-04 Technische Universität München Fgf-8 for use in treating diseases or disorders of energy homeostasis
AU2015218903B2 (en) 2014-02-20 2020-10-15 Allergan, Inc. Complement component C5 antibodies
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
CA2888068A1 (en) 2014-04-15 2015-10-15 The Hospital For Sick Children Cationic antimicrobial peptides
US20170073690A1 (en) 2014-05-15 2017-03-16 CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH Antagonists of slc38a9 and their use in therapy
WO2015179415A1 (en) 2014-05-19 2015-11-26 Novartis Ag Methods of treating anorexia
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016016859A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
WO2016025401A1 (en) 2014-08-09 2016-02-18 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances
CA2957717C (en) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
EA201790434A1 (ru) 2014-08-22 2017-07-31 Окленд Юнисервисиз Лимитед Модуляторы каналов
BR112017003986A2 (pt) 2014-08-27 2018-02-27 Peptimed Inc composições e métodos anti-tumor
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
EP3412302B1 (en) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
WO2016079321A1 (en) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
US10906948B2 (en) 2015-02-23 2021-02-02 Seagull Therapeutics Sas Non-natural Semaphorins 3 and their medical use
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CA2982682A1 (en) 2015-04-17 2016-10-20 Amgen Research (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
US10864190B2 (en) 2015-04-22 2020-12-15 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
US10676490B2 (en) 2015-07-07 2020-06-09 Florida Southwestern State College Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CA3000697A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
WO2017079215A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
WO2017081483A1 (en) 2015-11-13 2017-05-18 Mavalon Therapeutics Limited Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
HRP20211466T1 (hr) 2015-12-09 2021-12-24 Medizinische Universität Wien Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka
EA201891323A1 (ru) 2015-12-23 2019-02-28 Амген Инк. Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
KR20190031425A (ko) 2016-01-15 2019-03-26 함부르크대학교 O-람노실 잔기를 보유하는 플라보노이드-유형 화합물
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
US10301391B2 (en) 2016-02-03 2019-05-28 Amgen Research (Munich) Gmbh BCMA and CD3 bispecific T cell engaging antibody constructs
PL3411404T3 (pl) 2016-02-03 2023-02-13 Amgen Research (Munich) Gmbh Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
CN109153647A (zh) 2016-02-15 2019-01-04 分子医学研究中心责任有限公司 用于治疗癌症的taf1抑制剂
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
ES2952038T3 (es) 2016-04-05 2023-10-26 Univ New York State Res Found Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune
PL3280414T3 (pl) 2016-04-15 2024-06-24 Oxford University Innovation Limited Modulatory receptora adenozyny w leczeniu schorzeń rytmu okołodobowego
CN109071623B (zh) 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
EP3478830B1 (en) 2016-07-01 2024-04-10 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US20200030295A1 (en) 2016-08-02 2020-01-30 Friedrich-Alexander-Universität Erlangen-Nürnberg Heterocyclic diamidines
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
EP4559928A3 (en) 2016-10-19 2025-10-29 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
KR20190103154A (ko) 2016-11-14 2019-09-04 체엠엠 - 포르슝스첸트룸 퓨어 몰레쿨라레 메디친 게엠베하 암의 치료법을 위한 brd4 억제제 및 항폴레이트의 조합
US11091490B2 (en) 2016-11-30 2021-08-17 Medizinische Universität Innsbruck 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
AU2018261951B2 (en) 2017-05-05 2025-05-22 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US11180518B2 (en) 2017-05-12 2021-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
EP3621620A1 (en) 2017-05-12 2020-03-18 Mavalon Therapeutics Limited Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
MX2019015544A (es) 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
CN111278858B (zh) 2017-07-11 2024-07-23 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
JP2020528054A (ja) 2017-07-19 2020-09-17 オークランド ユニサービシズ リミテッド サイトカインモジュレーション
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
JP2020537506A (ja) 2017-10-04 2020-12-24 アムジエン・インコーポレーテツド トランスサイレチン免疫グロブリン融合物
US11066438B2 (en) 2017-10-30 2021-07-20 Enterin, Inc. Squalamine solid forms and methods of making the same
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3720850A1 (en) 2017-12-05 2020-10-14 ETH Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
CA3082507A1 (en) 2017-12-11 2019-06-20 Amgen Inc. Continuous manufacturing process for bispecific antibody products
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
CA3086205A1 (en) 2017-12-19 2019-06-27 Massachusetts Institute Of Technology Antigen-adjuvant coupling reagents and methods of use
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
BR122022000386B1 (pt) 2018-03-14 2022-09-27 Surface Oncology, Inc Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos
JP7328983B2 (ja) 2018-03-22 2023-08-17 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
IL316596A (en) 2018-03-30 2024-12-01 Amgen Inc C-terminal antibody variants
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
BR112020020464A2 (pt) 2018-04-06 2021-01-12 Zilentin AG Derivados de bumetanida para a terapia da hiperidrose
MA52205A (fr) 2018-04-09 2021-02-17 Amgen Inc Protéines de fusion du facteur de différenciation de croissance 15
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
KR20210019487A (ko) 2018-06-11 2021-02-22 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 스트레스 관련 장애 및 암의 치료를 위한 물질 및 방법
CN112912110A (zh) 2018-06-12 2021-06-04 安吉克公司 抗体-寡核苷酸缀合物
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
US12460004B2 (en) 2018-08-09 2025-11-04 Compass Therapeutics Llc Antibodies that bind CD277 and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
US12377294B2 (en) 2018-08-28 2025-08-05 Ambrx, Inc. Anti-CD3 antibody folate bioconjugates and their uses
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
MX2021003435A (es) 2018-09-28 2021-06-15 Massachusetts Inst Technology Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
JP7644706B2 (ja) 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CA3119161A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US12358978B2 (en) 2018-12-13 2025-07-15 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
EP3898614A1 (en) 2018-12-17 2021-10-27 Tolremo Therapeutics AG Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
AU2020204992A1 (en) 2019-01-04 2021-07-15 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
EP3914289A1 (en) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
CN120131907A (zh) 2019-03-19 2025-06-13 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3997112A1 (en) 2019-07-08 2022-05-18 Amgen, Inc Multispecific transthyretin immunoglobulin fusions
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
WO2021030251A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
BR112022002666A2 (pt) 2019-08-13 2022-08-09 Amgen Inc Muteínas de interleucina-2 para a expansão de células t reguladoras
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
EP4031178A1 (en) 2019-09-16 2022-07-27 Surface Oncology, Inc. Anti-cd39 antibody compositions and methods
JP2022549854A (ja) 2019-09-25 2022-11-29 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
WO2021064142A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
US12410152B2 (en) 2019-10-16 2025-09-09 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
WO2021081353A1 (en) 2019-10-23 2021-04-29 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
WO2021080682A1 (en) 2019-10-24 2021-04-29 Massachusetts Institute Of Technology Monoclonal antibodies that bind human cd161 and uses thereof
EP4534075A3 (en) 2019-10-28 2025-12-17 MedImmune Limited Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
AU2020386151B2 (en) 2019-11-19 2023-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
AU2020407208A1 (en) 2019-12-17 2022-06-02 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
KR20250095745A (ko) 2020-01-06 2025-06-26 백시넥스 인코포레이티드 항-ccr8 항체 및 이의 용도
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
JP7750852B2 (ja) 2020-03-19 2025-10-07 アムジエン・インコーポレーテツド ムチン１７に対する抗体及びその使用
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
BR112022026045A2 (pt) 2020-06-25 2023-01-17 Tolremo Therapeutics Ag Derivados heterocíclicos, composições farmacêutucas e seu uso no tratamento, melhora ou prevenção de doença fibrótica
CA3184076A1 (en) 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
EP4171614A1 (en) 2020-06-29 2023-05-03 Resolve Therapeutics, LLC Treatment of sjogren's syndrome with nuclease fusion proteins
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
BR112023002195A2 (pt) 2020-08-26 2023-03-14 Scancell Ltd Ácido nucleico que codifica um polipeptídeo, vetor, peptídeo, e composição de vacina
EP3964497A1 (en) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
AU2021359129A1 (en) 2020-10-16 2023-06-01 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
PE20231860A1 (es) 2020-11-06 2023-11-21 Amgen Inc Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
IL307402A (en) 2021-04-07 2023-12-01 Tolremo Therapeutics Ag The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer
AU2022264339A1 (en) 2021-04-28 2023-11-09 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
AU2022270170A1 (en) 2021-05-07 2023-09-21 Surface Oncology, LLC Anti-il-27 antibodies and uses thereof
CA3218000A1 (en) 2021-05-14 2022-11-17 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
CA3230815A1 (en) 2021-09-03 2023-03-09 University Of Bern Compositions and methods for treating long ot syndrome
MX2024005106A (es) 2021-11-03 2024-07-02 Affimed Gmbh Ligandos biespecificos de cd16a.
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
AU2023255339A1 (en) 2022-04-19 2024-12-05 Sasha A. PHILBERT Treatment of brain copper disorders
WO2023203172A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
IL316289A (en) 2022-04-29 2024-12-01 Purinomia Biotech Inc Methods and compositions for treating diseases and disorders driven by eosinophils
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
AR130384A1 (es) 2022-09-02 2024-12-04 Univ Of Bern Composiciones y métodos para tratar el síndrome de qt largo
CA3264260A1 (en) 2022-09-14 2024-03-21 Amgen Inc. BISPECIFIC MOLECULE STABILIZATION COMPOSITION
WO2024076995A1 (en) 2022-10-03 2024-04-11 Insigna Inc. Compositions for non-surgical prevention of boar taint and aggressive behavior
KR20250089547A (ko) 2022-10-25 2025-06-18 펩토믹, 에스.엘. 암 치료를 위한 조합 요법
EP4630537A1 (en) 2022-12-07 2025-10-15 Fondazione Matilde Tettamanti e Menotti de Marchi Onlus Methods for generating genetically modified cytokine induced killer (cik) cells
CN116272703B (zh) * 2023-02-01 2025-10-10 绍兴惠群新材料科技有限公司 纳米微球和基于非极性分子的纳米微球水相分散液的制备
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025040546A1 (en) 2023-08-18 2025-02-27 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025104236A1 (en) 2023-11-15 2025-05-22 Proxygen Gmbh Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
EP4616864A1 (en) 2024-03-11 2025-09-17 Peptomyc, S.L. Compound for the treatment of autoimmune diseases
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
SE7900458L (sv) * 1978-01-27 1979-07-28 Sandoz Ag Liposom-avgivningssystem for lekemedel
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4342826A (en) * 1980-02-04 1982-08-03 Collaborative Research, Inc. Immunoassay products and methods
GR77320B (enExample) * 1980-12-22 1984-09-11 Procter & Gamble

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306406B1 (en) 1990-07-19 2001-10-23 University Of Kentucky Research Foundation Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer

Also Published As

Publication number Publication date
DK157063B (da) 1989-11-06
DK67483D0 (da) 1983-02-16
NO830521L (no) 1983-08-18
AU1149083A (en) 1983-08-25
EP0088046A2 (de) 1983-09-07
PT76245A (de) 1983-03-01
FI830486L (fi) 1983-08-18
DK67483A (da) 1983-08-18
ES519810A0 (es) 1984-08-16
IE830318L (en) 1983-08-23
GR81377B (enExample) 1984-12-11
NO168154B (no) 1991-10-14
EP0088046B1 (de) 1987-12-09
FI830486A0 (fi) 1983-02-14
DK157063C (da) 1990-04-09
ES8407061A1 (es) 1984-08-16
DE3374837D1 (en) 1988-01-21
NO168154C (no) 1992-01-22
IL67916A0 (en) 1983-06-15
US4619794A (en) 1986-10-28
CA1219215A (en) 1987-03-17
FI79245C (fi) 1989-12-11
FI79245B (fi) 1989-08-31
AU558810B2 (en) 1987-02-12
PT76245B (de) 1986-02-04
IE54642B1 (en) 1989-12-20
EP0088046A3 (en) 1984-02-08

Similar Documents

Publication Publication Date Title
US4619794A (en) Spontaneous preparation of small unilamellar liposomes
EP0102324A2 (de) Lipide und Tenside in wässriger Phase
CA1246446A (en) Process for the manufacture of pharmaceutical compositions containing unilamellar liposomes
US5277914A (en) Preparation of liposome and lipid complex compositions
EP0219922B1 (en) Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US5549910A (en) Preparation of liposome and lipid complex compositions
US5043164A (en) Blood-stable, cholesterol-free liposomes
EP0966267B1 (en) N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6759057B1 (en) Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4755388A (en) Liposome-encapsulated 5-fluoropyrimidines and methods for their use
EP0249561B1 (en) Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
EP0272091A2 (en) Delivery vehicles with amphiphile-associated active ingredient
EP0467954B1 (en) Preparation of liposome and lipid complex compositions
KR960013282B1 (ko) 친유성약품을 함유하는 리포조옴 제조를 위한 여러단계의 포착/충전방법
Patel et al. Modification of vesicle surfaces with amphiphilic sterols. Effect on permeability and in vivo tissue distribution
CA2269502C (en) Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraetherlipid derivatives, and use thereof
JP3399009B2 (ja) リポソームの製造方法
WO1991006310A1 (en) Liposomal compositions
US20060062839A1 (en) Efficient liposomal encapsulation under mild conditions
EP0510197A1 (en) Fat emulsion
JP2700276B2 (ja) リポソーム
Perry Nuclear magnetic resonance studies of biological molecules
WO2003057189A1 (en) Efficient liposomal encapsulation under mild conditions
JPWO1997048398A1 (ja) インドロカルバゾール誘導体のリポソーム製剤
HK1000912B (en) Preparation of liposome and lipid complex compositions